Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings

Chung, Hyun Hoon; Kang, Won Jun; Kim, Jae Weon; Park, Noh-Hyun; Song, Yong Sang; Chung, June‐Key; Kang, Sungwoo; Lee, Hyo-Pyo

doi:10.1007/s00259-006-0260-x

Cited by 104 publications

(46 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the prior studies, researchers found that accuracy, sensitivity, and specifi city were 63%-100%, 73%-100%, and 40%-100%, respectively, at the patient level and 72%-96%, 41%-78%, and 75%-99%, respectively, at the region level ( 14,16,17,20,(25)(26)(27)(28)(29)(30). In these prior studies, the diagnostic The number, size (on CE CT and PET/CT images) and SUV max (on PET/CT images) of peritoneal deposits (for all three readers) and of distant (M1) lymph node metastases (readers 1 and 2 only) were signifi cantly associated with poor survival ( Table 5 ).…”

Section: Discussionmentioning

confidence: 99%

Recurrent Ovarian Cancer: Use of Contrast-enhanced CT and PET/CT to Accurately Localize Tumor Recurrence and to Predict Patients’ Survival

Sala¹,

Kataoka²,

Pandit‐Taskar³

et al. 2010

Radiology

View full text Add to dashboard Cite

Purpose:To compare accuracy and interobserver variability in the detection and localization of recurrent ovarian cancer with contrast material-enhanced (CE) computed tomography (CT) and positron emission tomography (PET)/CT and determine whether imaging fi ndings can be used to predict survival. Materials and Methods:Waiving informed consent, the institutional review board approved this HIPAA-compliant, retrospective study of 35 women (median age, 54.4 years) with histopathologically proven recurrent ovarian carcinoma who underwent CE CT and PET/CT before exploratory surgery. All CE CT and PET /CT scans were independently analyzed. Tumor presence, number of lesions, and the size and maximum standardized uptake value (SUV max ) of the largest lesion were recorded for patient and region. Surgical histopathologic fi ndings constituted the reference standard. Areas under the receiver operating characteristic curves (AUCs), k statistics, and hazard ratios were calculated. Results:Readers' AUCs in detection of recurrence for region were 0.85 (95% confi dence interval [CI]: 0.81, 0.90) and 0.78 (95% CI: 0.72, 0.83) for CE CT and 0.84 (95% CI: 0.79, 0.89) and 0.74 (95% CI: 0.67, 0.81) for PET/CT ( P = .76); 12 patients died. At PET/CT, size, number, and SUV max of peritoneal deposits were signifi cantly associated with poor survival for readers 1 and 2 ( P Յ .01 and Յ .05, respectively), as were long-and short-axis diameters, number, and SUV max of distant lymph nodes for reader 1 ( P Յ .001).With CE CT, size (reader 1) and number (readers 1 and 3) of peritoneal deposits were signifi cantly associated with poor survival ( P Յ .01), as were long-and short-axis diameters and number of distant lymph nodes for reader 1 ( P Յ .01). Interobserver agreement ranged from fair (patient, k = 0.30) to moderate (region, k = 0.55) for CE CT and fair (patient, k = 0.24) to substantial (region, k = 0.63) for PET/CT. Conclusion:Preliminary data suggest that CE CT and PET/CT may have similar accuracy in detection of recurrent ovarian cancer. Tumor size, number, and SUV max may have potential as prognostic biomarkers for patients with recurrent ovarian cancer.q RSNA, 2010

show abstract

Section: Discussionmentioning

confidence: 99%

Recurrent Ovarian Cancer: Use of Contrast-enhanced CT and PET/CT to Accurately Localize Tumor Recurrence and to Predict Patients’ Survival

Sala¹,

Kataoka²,

Pandit‐Taskar³

et al. 2010

Radiology

View full text Add to dashboard Cite

show abstract

“…Integrated PET/CT had an impact on management in 44% of patients in a retrospective review of 32 patients, and PET/CT detected tumor relapse in a higher percentage of patients than could CT (53). The impact on management has been confirmed in a larger series of patients (54), including a questionnaire-based study that showed PET/CT allows a better restaging than does CT and induces a change in clinical management in over one third of patients with suspected ovarian carcinoma recurrence based on increased CA-125 levels (55). Figure 4 illustrates the example of a patient in whom 18 F-FDG PET/CT detected recurrence and later also documented progressive disease with therapy.…”

Section: Detection Of Recurrent or Metastatic Diseasementioning

confidence: 88%

The Role of ¹⁸F-FDG PET in Assessing Therapy Response in Cancer of the Cervix and Ovaries

Schwarz¹,

Grigsby²,

Dehdashti³

et al. 2009

J Nucl Med

101

View full text Add to dashboard Cite

“…In the last years, FDG-PET/CT has been utilized to identify clinically occult recurrent ovarian cancer, inorder to improvethe earlier detection of relapse and consequently increase the possibility of secondary cytoreduction [17,18,19,20,21,22,23,24,25,26]. The accuracy rate has ranged from 70 to 95%, and it is limited by the inability to detect small volume (≤7 mm) disease and the misinterpretation of normal physiological abdominal activity [17, 27].…”

Section: Discussionmentioning

confidence: 99%

“…Recently, a growing body of evidence has been produced for the use of fluorine-18-fluorodeoxyglucose positive emission tomography (FDG-PET) and PET/computed tomography (CT) in the early diagnosis of recurrence in ovarian cancer patients [17,18,19,20,21,22,23,24,25,26]. Nevertheless, this technique is still limited by small nodule carcinosis [17,18,19,20,21,22,23,24,25,26,27]. Moreover, no data are available regarding the ability of FDG-PET/CT to assess diffusion of advanced intra-/retroperitoneal disease, and its correlation with the possibility of complete cytoreduction.…”

Section: Introductionmentioning

confidence: 99%

A Treatment Selection Protocol for Recurrent Ovarian Cancer Patients: The Role of FDG-PET/CT and Staging Laparoscopy

et al. 2008

View full text Add to dashboard Cite

Objective: To investigate the best diagnostic and staging strategy for recurrent ovarian cancer. Methods: The negative predictive value, specificity, positive predictive value, sensitivity, and accuracy rates of the fluorine-18-fluorodeoxyglucose positive emission tomography computed tomography (FDG-PET/CT) and staging laparoscopy in identifying surgically treatable/untreatable patients are assessed in a consecutive series of 70 recurrent ovarian cancer cases. Moreover, the diagnostic performance of each staging procedure in the evaluation of the number of nodules is analyzed. Results: The negative predictive value of the FDG-PET/CT was 83.3%, whereas the positive predictive value was 76.9%. Specificity was 55.6%, whereas sensitivity was 93.0%. Accuracy rate was 78.6%. Negative predictive value, specificity, positive predictive value, sensitivity, and accuracy rate of staging laparoscopy were 88.9, 64.0, 80.8, 95.0 and 83.1%, respectively. Combined radiological and laparoscopic evaluation showed a negative predictive value of 88.9%, a specificity of 59.3%, a positive predictive value of 78.8%, a sensitivity of 95.3%, and an accuracy rate of 81.4%. The number of nodules identified by FDG-PET/CT corresponded in only 23 patients (40.3%) at laparotomy, whereas 15 of 30 patients were correctly diagnosed (50.0%) by staging laparoscopy. Conclusions: The combination of FDG-PET/CT and staging laparoscopy has a significant effect on the multimodal approach to the population of patients with recurrent ovarian cancer. Such techniques should be considered complementary, because of the potential of each one to identify a different setting of the disease.

show abstract

Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings

Abstract: Integrated FDG PET/CT is a sensitive post-therapy surveillance modality for the detection of recurrent ovarian cancer; it aids decisions on treatment plans and may ultimately have a favourable impact on prognosis.

Cited by 104 publications

References 28 publications

Recurrent Ovarian Cancer: Use of Contrast-enhanced CT and PET/CT to Accurately Localize Tumor Recurrence and to Predict Patients’ Survival

Recurrent Ovarian Cancer: Use of Contrast-enhanced CT and PET/CT to Accurately Localize Tumor Recurrence and to Predict Patients’ Survival

The Role of ¹⁸F-FDG PET in Assessing Therapy Response in Cancer of the Cervix and Ovaries

A Treatment Selection Protocol for Recurrent Ovarian Cancer Patients: The Role of FDG-PET/CT and Staging Laparoscopy

Contact Info

Product

Resources

About

Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings

Abstract: Integrated FDG PET/CT is a sensitive post-therapy surveillance modality for the detection of recurrent ovarian cancer; it aids decisions on treatment plans and may ultimately have a favourable impact on prognosis.

Cited by 104 publications

References 28 publications

Recurrent Ovarian Cancer: Use of Contrast-enhanced CT and PET/CT to Accurately Localize Tumor Recurrence and to Predict Patients’ Survival

Recurrent Ovarian Cancer: Use of Contrast-enhanced CT and PET/CT to Accurately Localize Tumor Recurrence and to Predict Patients’ Survival

The Role of 18F-FDG PET in Assessing Therapy Response in Cancer of the Cervix and Ovaries

A Treatment Selection Protocol for Recurrent Ovarian Cancer Patients: The Role of FDG-PET/CT and Staging Laparoscopy

Contact Info

Product

Resources

About

The Role of ¹⁸F-FDG PET in Assessing Therapy Response in Cancer of the Cervix and Ovaries